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Abstract  
Aim of the study:  The anti-osteoporotic activity of Erxian 
Decoction, a Chinese medicinal formula, in a rat model of 
menopausal osteoporosis was evaluated by microcomputed 
tomography (microCT). 
Materials and methods: Menopause causes a decline in both 
endocrine function and bone mineral density in human. In this 
study, 20-month-old female Sprague-Dawley-rats (SD-rats) with 
a low serum estradiol level and bone mineral density were 
employed. The anti-osteoporotic activity of EXD was assessed 
by the determination of trabecular material bone mineral density 
at the L2 mid-vertebral body after treatment. Serum estrogen 
levels were also determined to assess the effect of EXD on the 
endocrine status.  
Results: Results revealed a significant elevation in serum 
estradiol level and trabecular bone mineral density at the L2 
mid-vertebral body in the EXD-treated menopausal rat model.  
Conclusions:  
The results obtained from the present investigation revealed that 
the EXD had anti-osteoporotic activity as evidenced by an 
increase of serum estradiol level and bone mineral density.  
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1. Introduction 
Menopause is the period during which estrogen secreted 
by the ovaries gradually declines and patients suffer from much 
higher incidences of body and mental changes, such as 
oesteoporsis [3]. It is also believed the low levels of estrogen in 
patients are responsible for the peri-menopausal symptoms, 
including osteoporosis [3]. Menopause is normally treated by 
hormone replacement therapy. However, such treatment may 
increase the incidence of different side effects, i.e. breast cancer 
and stroke [2]. Therefore, scientists are seeking safer and more 
effective alternatives [1]. 
Erxian Decoction (EXD), a popular Chinese medicinal 
formula, has been clinically used in the treatment of menopausal 
syndrome for more than 50 years. Nian et al. (2006) and Qin et 
al. (2008) reported that EXD and its chemical constituents 
possessed antiosteoporotic activity in ovariectomized rats and it 
increased the serum estradiol level [3, 4]. The L2 mid-vertebral 
body has been used clinically for assessment of osteoporosis [5]. 
However, the utility of micro-CT imaging in evaluating the 
efficacy of the Chinese medicinal formula, EXD, on anti-
osteoporosis regimen has not been reported. In this study, we 
propose to evaluate the anti-osteoporotic activity of EXD by 
measuring the trabecular material bone mineral density at the L2 
mid-vertebral body. 
 
2. Materials and methods: 
2.1 Herbal materials  
 Six herbal materials, including Curculigo orchioides, 
Epimedium brevicornum, Morinda officinalis How, Angelica 
sinensis, Phellodendron chinense and Anemarrhena 
asphodeloides (bearing voucher numbers. CME140706-03, 
CME150906-11, CME050406-02, CME090706-12, 
CME100606-09, and CME180806-01, respectively) were 
collected from various sources and their identities were 
confirmed by Professor Zhengtao Wang, Department of 
Pharmacognosy, China Pharmaceutical University. The voucher 
specimens were kept in the China Pharmaceutical University.   
 
2.2 Preparation of EXD 
 One kilograms of a mixture of the six medicinal 
materials was extracted by decocting it with distilled water, 10:1 
(v/w), at 100℃ for 1 h. The extraction was repeated twice. The 
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filtrates were lyophilized in a freeze drier (Labconco, Freezone), 
and kept at 4℃ for quality control and molecular studies. The 
yield of dried extract from the starting crude materials was 20%.  
 
2.3 Animals 
Twelve-month-old female Sprague–Dawley (SD) rats, 
with a low serum estradiol level and trabecular bone mineral 
density, were employed as a menopausal animal model in this 
study. Female SD rats, aged 8 months, were purchased from the 
Laboratory Animal Unit, the University of Hong Kong. The 
animals were housed in an air-conditioned room at an ambient 
temperature of 24℃ and 50-65% relative humidity under a 12 h 
light: 12 h dark photoperiod. They were acclimated for 4 months 
and their serum estradiol levels monitored before the 
experiment. The experiment had been approved by the 
Committee on the Use of Live Animals in Teaching and 
Research (CULATR) of Li Ka Shing Faculty of Medicine, the 
University of Hong Kong. 
 
2.4 Drug administration and sera collections 
Rats were randomly divided into four groups of 10 
animals each. The Chinese medicinal EXD extract (0.76 and 
1.52 g/kg) and the Western medicine Premarin capsule (31.25 
mg/kg) (each capsule containing 0.3 mg of estrogen) were 
separately administered by the oral route, everyday for 6 weeks. 
The control group received orally an equal volume of water 
instead of EXD. At the end of the experiment, the rats were 
anesthetized by an intraperitoneal injection of ketamine (80 
mg/kg) and xylazine (10 mg/kg) dissolved in 0.9% saline. Their 
sera and L1-6 mid-vertebrae were collected and stored at -80℃ 
for further analysis.  
 
2.5 Detection of serum estradiol level 
The estradiol levels in serum samples were determined by 
using the electro-chemiluminescence immunoassay (Elecsys 
1010; Roche Diagnostics), following the manufacturer’s 
instructions. 
 
2.6 Measurement of bone mineral density 
The lumbar vertebrae in each group were harvested for 
trabecular bone mineral density assessment by microcomputed 
tomography (microCT). The isolated lumbar vertebrae from the 
four group of rats were placed inside a sample holder and the 
long axis aligned with the axis of rotation of the X-ray gantry. A 
scout view was obtained to identify the 2nd lumbar vertebra 
(L2). Then a set of 100 axial slices at a resolution of 21 μm was 
acquired at the L2 mid-vertebral body with 70 KV and 110 μA 
using an In Viva MicroCT 40 computed tomography system 
(Scanco Medical, Basserdorf, Switzerland). Volume rendering 
of these slices was performed to provide a three-dimensional 
(3D) image. The trabecular material bone mineral density was 
automatically evaluated using the built-in program of the 
microCT with direct 3D morphometry. One-way ANOVA was 
employed to find out any significant difference. 
 
3. Result and discussion: 
Our recent study showed that EXD with anti-osteoporosis 
can increase the trabecular bone mineral density at L2 mid-
vertebral body [Fig 1A &4B]. Osteoporosis is one of the major 
menopausal symptoms. The trabecular bone mineral density at 
L2 mid-vertebral body has been used clinically for assessment 
of osteoporosis [5]. Estrogen deficiency is known to be an 
important contributing factor in the pathogenesis of 
osteoporosis. EXD treatment can increase the level of estrogen 
in old female rats [Table 1]. The loss of estrogen has been 
related to an increase in the bone remodeling rate which results 
in a negative bone balance. This finding demonstrated that EXD 
brought about a reversal of the negative bone balance with an 
increase in trabecular bone mineral density compared with the 
control. In addition, a significant linear trend effect was also 
demonstrated with the use of EXD [Fig 1D]. In conclusion, 
EXD exhibited an anti-resorptive effect, reduced the frequency 
of bone remodelling events and allowed a full degree of bone 
mineralisation. We are the first group to demonstrate that EXD 
treatment can increase trabecular bone mineral density at the L2 
mid-vertebral body. Therefore, the trabecular bone mineral 
density will be used as a biomarker to assess the efficacies of the 
other Chinese herbs and their constituents for relieving 
menopausal osteoporosis.  
 
4. Conclusion: 
Twenty-month-old female SD rats prescribed with EXD 
showed a higher trabecular material bone mineral density at the 
L2 mid-vertebral body and serum estrogen level than the intact 
control. Results obtained from this study could provide a simple 
and authentic strategy for investigating menopausal osteoporosis 
that may open new alternatives for the treatment of menopausal 
osteoporosis.  
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Figure and Table 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1. MicroCT scan of 20-month-Old SD rats showing L2 vertebral body trabecular bone from the various groups. Fig 1A (high dose 
EXD, 1.52 g/kg/day, 6 weeks); Fig 1B (low dose EXD, 0.76 g/kg/day, 6 weeks); Fig 1C (Intact control); Fig 1D After analysis, the 
high dose EXD (HTCM) had a trabecular BMD of 2.7 % and 6.8 % higher than the low dose EXD (LTCM) and intact control group, 
respectively, ( ** P < 0.05) whereas that of the LTCM group was 4.1% higher than the intact control (* P= 0.005). Analysis with 
ANOVA with LSD post hoc test. Ascending trend increase was shown from intact control to High dose EXD group. 
 
 
Table 1 
Effect of EXD on serum estradiol level (n=10, mean±SD) 
Group estradiol level (pg/ml) 
Young rat group (3-month-old SD rats) 225.6±73.6 
Control group (12-month-old SD rats) 58.9±21.2## 
EXD-treated group (0.76 g/kg) 93.2±33.5* 
EXD-treated group (1.52 g/kg)  170.2±54.6** 
## P<0.01 compared with young rat group；* P<0.05, ** P<0.01 compared with old rat group. (The data in this table were 
published in Journal of Ethnopharmacology, [6]) 
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